<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2023-10-15</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПЕРЕДОВАЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LEADING ARTICLE</subject></subj-group></article-categories><title-group><article-title>К 100-летию со дня рождения академика В.А. Насоновой. Инфекции и ревматические заболевания: от прошлого к будущему</article-title><trans-title-group xml:lang="en"><trans-title>To the 100th anniversary of the birth of academician V.A. Nasonova. Infections and rheumatic diseases: from the past to the future</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7091-2054</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белов</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Белов Борис Сергеевич </p><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а </p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A </p></bio><email xlink:type="simple">belovbor@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1598-8360</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A </p><p>119991, Russian Federation, Moscow, Trubetskaya str., 8, building 2 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;&#13;
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology;&#13;
I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>03</month><year>2023</year></pub-date><volume>61</volume><issue>1</issue><fpage>10</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Белов Б.С., Насонов Е.Л., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Белов Б.С., Насонов Е.Л.</copyright-holder><copyright-holder xml:lang="en">Belov B.S., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3272">https://rsp.mediar-press.net/rsp/article/view/3272</self-uri><abstract><p>В ревматологии проблема инфекционной патологии стоит достаточно остро. Это обусловлено, в первую очередь, участием различных инфекционных агентов в развитии иммуновоспалительных ревматических заболеваний (ИВРЗ), при которых микроорганизмы играют триггерную роль, запуская иммунопатологические механизмы воспаления. Яркими примерами таких болезней являются острая ревматическая лихорадка и реактивные артриты. Доказана инфекционная этиология болезни Лайма. Не менее сложную задачу представляет собой борьба с коморбидной инфекцией (КИ), нередко осложняющей течение многих ИВРЗ из-за нарушения иммунного статуса, обусловленного как фоновым заболеванием, так и применением иммуносупрессивных препаратов. Преобладание в структуре КИ поражения дыхательных путей у больных ИВРЗ обусловливает необходимость применения у них гриппозных и пневмококковых вакцин, поскольку риск летальных исходов от указанных инфекций среди этих пациентов достаточно высок. В процессе развития пандемии COVID-19, явившейся вызовом всему человечеству, вскрылось большое число новых фундаментальных и медицинских проблем, касающихся взаимоотношений вирусной инфекции и многих распространенных хронических неинфекционных заболеваний, среди которых важную позицию занимают ИВРЗ. В качестве одного из методов борьбы с текущей пандемией COVID-19 большие надежды возлагаются на широкое применение вакцинации. Обсуждается возможность применения моноклональных антител для доконтактной профилактики COVID-19, в том числе у пациентов с ИВРЗ.</p></abstract><trans-abstract xml:lang="en"><p>In rheumatology, the problem of infectious pathology is quite acute. This is primarily due to the participation of various infectious agents in the development of immuno-inflammatory rheumatic diseases (IIRD), in which microorganisms play a trigger role, triggering the immunopathological mechanisms of inflammation. Vivid examples of such diseases are acute rheumatic fever and reactive arthritis. The infectious etiology of Lyme disease has been proven. An equally difficult task is the fight against comorbid infection (CI), which often complicates the course of many IIRD due to a violation of the immune status caused by both the background disease and the use of immunosuppressive drugs. The predominance of respiratory tract lesions in the structure of CI in patients with IIRD makes it necessary to use influenza and pneumococcal vaccines in them, since the risk of deaths from these infections among these patients is quite high. During the development of the COVID-19 pandemic, which has become a challenge to all mankind, a large number of new fundamental and medical problems have been revealed concerning the relationship between viral infection and many widespread chronic non-communicable diseases, among which IIRDs occupy an important position. As one of the methods of combating the current COVID-19 pandemic, great hopes are pinned on the widespread use of vaccination. The possibility of using mo noclonal antibodies for pre-exposure prophylaxis of COVID-19, including in patients with IIRD, is discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>иммуновоспалительные ревматические заболевания</kwd><kwd>острая ревматическая лихорадка</kwd><kwd>реактивные артриты</kwd><kwd>болезнь Лайма</kwd><kwd>COVID-19</kwd><kwd>коморбидные инфекции</kwd><kwd>вакцинопрофилактика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immuno-inflammatory rheumatic diseases</kwd><kwd>acute rheumatic fever</kwd><kwd>reactive arthritis</kwd><kwd>Lyme disease</kwd><kwd>COVID-19</kwd><kwd>comorbid infections</kwd><kwd>vaccination</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», № государственного задания 1021051503137-7.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Нестеров АИ. Ревматизм. М.:Медицина;1973.</mixed-citation><mixed-citation xml:lang="en">Nesterov AI. Rheumatism. Moscow:Meditsina;1973 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонова ВА, Бронзов ИА. Ревматизм. М.:Медицина;1978.</mixed-citation><mixed-citation xml:lang="en">Nasonova VA, Bronzov IA. Rheumatism. Moscow:Meditsina;1978 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Джузенова БС, Котельникова ГП, Михайлова ИН, Насонова ВА. Острый ревмокардит у молодых мужчин. Терапевтический архив. 1992;64(4):58-62.</mixed-citation><mixed-citation xml:lang="en">Dzhuzenova BS, Kotelnikova GP, Mikhaylova IN, Nasonova VA. Acute rheumocarditis in young men. Terapevticheskii arkhiv. 1992;64(4):58-62 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Насонова ВА, Кузьмина НН, Белов Б.С. Классификация и номенклатура ревматической лихорадки. Научно-практическая ревматология. 2004;42(2):48-52.</mixed-citation><mixed-citation xml:lang="en">Nasonova VA, Kuzmina NN, Belov BS. Classification and nomenclature of rheumatic fever. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2004;42(2):48-52 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Панасюк АФ, Солдатова СИ, Шубин СВ, Колкова НИ. О патогенетических аспектах урогенных артритов, ассоциированных с хламидиями: возможность микроорганизмов размножаться в клетках суставного хряща. Терапевтический архив. 1998;70(5):45-48.</mixed-citation><mixed-citation xml:lang="en">Panasyuk AF, Soldatova SI, Shubin SV, Kolkova NI. On the pathogenetic aspects of urogenic arthritis associated with chlamydia: The possibility of microorganisms to multiply in the cells of articular cartilage. Terapevticheskii arkhiv. 1998;70(5):45-48 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Сидельникова СМ, Агабабова ЭР, Стысин ЕА. Клиническая симптоматика и некоторые вопросы терапии болезни Рейтера. Терапевтический архив. 1978;50(6):99-103.</mixed-citation><mixed-citation xml:lang="en">Sidelnikova SM, Agababova ER, Stysin EA. Clinical symptoms and some issues of Reiter’s disease therapy. Terapevticheskii arkhiv. 1978;50(6):99-103 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Агабабова ЭР. Развитие исследований по проблеме связанных с инфекциями артритов в Институте ревматологии РАМН в 70–80-х годах. Вестник Российской академии медицинских наук. 1998;12:23-26.</mixed-citation><mixed-citation xml:lang="en">Agababova ER Development of studies of the arthritis associated with infections at the Institute of rheumatology, Russian Academy of Medical Sciences, in the 1970s to the 1990s. Annals of the Russian Academy of Medical Sciences. 1998;12:23-26 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ананьева ЛП, Барскова ВГ, Конева ОА, Ушакова МА, Май ЭС, Пушкова ОВ, и др. Поражение суставов при иксодовых клещевых боррелиозах (лаймской болезни). Вестник Российской академии медицинских наук. 2003;7:42-47.</mixed-citation><mixed-citation xml:lang="en">Ananyeva LP, Barskova VG, Koneva OA, Ushakova MA, Mai ES, Pushkova OV. et al. Joint damage in ixodic tick-borne borreliosis (Lyme disease). Annals of the Russian Academy of Medical Sciences. 2003;7:42-47 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Конева ОА, Ананьева ЛП. Динамика антител к Borrelia burgdorferi на фоне антибактериальной терапии у пациентов с воспалительной артропатией при болезни Лайма. Научнопрактическая ревматология. 2002;40(2):42. doi: 10.14412/1995-4484-2002-105</mixed-citation><mixed-citation xml:lang="en">Koneva OA, Ananyeva LP. Dynamics of antibodies to Borrelia burgdorferi against the background of antibacterial therapy in patients with inflammatory arthropathy in Lyme disease. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2002;40(2):38 (In Russ.). doi: 10.14412/1995-4484-2002-105</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ (ред.). Ревматология: клинические рекомендации. М.:ГЭОТАР-Медиа;2011.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL (ed.). Rheumatology: Clinical guidelines. Moscow:GEOTAR-Media;2011 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Буханова ДВ, Белов БС, Тарасова ГМ, Соловьев СК, Ананьева ЛП, Попкова ТВ, и др. Коморбидные инфекции при ревматических заболеваниях (по данным ФГБНУ НИИР им. В.А. Насоновой). Медицинский совет. 2019;(9):86-91. doi: 10.21518/2079-701X-2019-9-86-91</mixed-citation><mixed-citation xml:lang="en">Bukhanova DV, Belov BS, Tarasova GM, Soloviev SK, Ananyeva LP, Popkova TV, et al. Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova). Medical Council. 2019;(9):86-91 (In Russ.). doi: 10.21518/2079-701X-2019-9-86-91</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Баранова ММ, Муравьева НВ, Белов БС, Глухова СИ, Коротаева ТВ. Коморбидные инфекции у больных спондилоартритами, получающих современную антиревматическую терапию (предварительные данные). Научно-практическая ревматология. 2022;60(4):455-459. doi: 10.47360/1995-4484-2022-455-459</mixed-citation><mixed-citation xml:lang="en">Baranova MM, Muravyeva NV, Belov BS, Glukhova SI, Korotaeva T.V. Comorbid infections in patients with spondyloarthritis who received modern antirheumatic therapy (preliminary data). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):455-459 (In Russ.). doi: 10.47360/1995-4484-2022-455-459</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2022 Nov 3:ard-2022-223335. doi: 10.1136/ard-2022-223335</mixed-citation><mixed-citation xml:lang="en">Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2022 Nov 3:ard-2022-223335. doi: 10.1136/ard-2022-223335</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Буханова ДВ, Белов БС, Тарасова ГМ, Эрдес Ш, Дубинина ТВ, Лукина ГВ, и др. Эффективность, безопасность и иммуногенность трехвалентной инактивированной сплитвакцины против гриппа у пациентов с ревматическими заболеваниями. Медицинский совет. 2018;(12):106-110. doi: 10.21518/2079-701X-2018-12-106-110</mixed-citation><mixed-citation xml:lang="en">Bukhanova DV, Belov BS, Tarasova GM, Erdes S, Dubinina TV, Lukina GV, et al. Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases. Medical Council. 2018;(12):106-110 (In Russ.). doi: 10.21518/2079-701X-2018-12-106-110</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Белов БС, Муравьева НВ, Тарасова ГМ, Баранова ММ, Сергеева МС, Черкасова МВ, и др. Вакцинопрофилактика невмококковой инфекции при ревматических заболеваниях: 10-летний опыт применения в ФГБНУ НИИР им. В.А. Насоновой. Научно-практическая ревматология. 2022;60(3):261-266. doi: 10.47360/1995-4484-2022-261-266</mixed-citation><mixed-citation xml:lang="en">Belov BS, Muravyeva NV, Tarasova GM, Baranova MM, Sergeeva MS, Cherkasova MV, et al. Pneumococcal vaccination in rheumatic diseases: 10 years of application experience at the V.A. Nasonova Research Institute of Rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(3):261-266 (In Russ.). doi: 10.47360/1995-4484-2022-261-266</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): вклад ревматологии. Терапевтический архив. 2021;93(5):537- 550. doi: 10.26442/00403660.2021.05.200799</mixed-citation><mixed-citation xml:lang="en">Nasonov EL. 2019 coronavirus disease (COVID-19): Contribution of rheumatology. Terapevticheskii arkhiv. 2021;93(5):537-550 (In Russ.). doi: 10.26442/00403660.2021.05.200799</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">A clinical case definition of post COVID-19 condition by a Delphi consensus. 6 October 2021. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (Accessed: DD Month 2022).</mixed-citation><mixed-citation xml:lang="en">A clinical case definition of post COVID-19 condition by a Delphi consensus. 6 October 2021. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (Accessed: DD Month 2022).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. doi: 10.47360/1995-4484-2021-239-254.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.) doi: 10.47360/1995-4484-2021-239-254.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Куликов АН, Муравьева НВ, Белов БС. Безопасность комбинированной векторной вакцины Гам-КОВИД-Вак (Спутник V) у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные. Антибиотики и химиотерапия. 2022;67(7-8):33-39. doi: 10.37489/0235-2990-2022-67-7-8-33-39</mixed-citation><mixed-citation xml:lang="en">Kulikov AN, Muravyeva NV, Belov BS. Safety of Gam-COVID-Vac (Sputnik V) combined vector vaccine in patients with immunoinflammatory rheumatic diseases: Preliminary data. Antibiotics and Chemotherapy. 2022;67(7-8):33-39 (In Russ.). doi: 10.37489/0235-2990-2022-67-7-8-33-39</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Белов БС, Лила АМ, Насонов ЕЛ. Вакцинация против SARSCoV-2 при ревматических заболеваниях: вопросы безопасности. Научно-практическая ревматология. 2022;60(1):21-31. doi: 10.47360/1995-4484-2022-21-31</mixed-citation><mixed-citation xml:lang="en">Belov BS, Lila AM, Nasonov EL. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(1):21-31 (In Russ.). doi: 10.47360/1995-4484-2022-21-31</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, et al. AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis of symptomatic COVID-19. Clin Infect Dis. 2022 Nov 22:ciac899. doi: 10.1093/cid/ciac899</mixed-citation><mixed-citation xml:lang="en">Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, et al. AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis of symptomatic COVID-19. Clin Infect Dis. 2022 Nov 22:ciac899. doi: 10.1093/cid/ciac899</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al.; TACKLE study group. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985-996. doi: 10.1016/S2213-2600(22)00180-1</mixed-citation><mixed-citation xml:lang="en">Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al.; TACKLE study group. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985-996. doi: 10.1016/S2213-2600(22)00180-1</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ocon AJ, Mustafa SS. Real-world experience of tixagevimab and cilgavimab (evusheld) in rheumatologic patients on rituximab. J Clin Rheumatol. 2022 Sep 20. doi: 10.1097/RHU.0000000000001907</mixed-citation><mixed-citation xml:lang="en">Ocon AJ, Mustafa SS. Real-world experience of tixagevimab and cilgavimab (evusheld) in rheumatologic patients on rituximab. J Clin Rheumatol. 2022 Sep 20. doi: 10.1097/RHU.0000000000001907</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Calabrese C, Kirchner E, Villa-Forte A, Hajj-Ali RA, Moss BP, Fernandez JP, et al. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. RMD Open. 2022;8(2):e002557. doi: 10.1136/rmdopen-2022-002557</mixed-citation><mixed-citation xml:lang="en">Calabrese C, Kirchner E, Villa-Forte A, Hajj-Ali RA, Moss BP, Fernandez JP, et al. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. RMD Open. 2022;8(2):e002557. doi: 10.1136/rmdopen-2022-002557</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Montastruc F, Lafaurie M, Flumian C, de Canecaude C. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for COVID-19. Clin Microbiol Infect. 2022 Dec 1:S1198-743X(22)00599-7. doi: 10.1016/j.cmi.2022.11.026</mixed-citation><mixed-citation xml:lang="en">Montastruc F, Lafaurie M, Flumian C, de Canecaude C. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for COVID-19. Clin Microbiol Infect. 2022 Dec 1:S1198-743X(22)00599-7. doi: 10.1016/j.cmi.2022.11.026</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Piszczek J, Murthy S, Afra K. Cardiac and vascular serious adverse events following tixagevimab-cilgavimab. Lancet Respir Med. 2022 Dec 12: S2213-2600(22)00452-0. doi: 10.1016/S2213-2600(22)00452-0</mixed-citation><mixed-citation xml:lang="en">Piszczek J, Murthy S, Afra K. Cardiac and vascular serious adverse events following tixagevimab-cilgavimab. Lancet Respir Med. 2022 Dec 12: S2213-2600(22)00452-0. doi: 10.1016/S2213-2600(22)00452-0</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
